2004
DOI: 10.3109/2000-1967-083
|View full text |Cite
|
Sign up to set email alerts
|

Development and possible clinical use of antagonists for PDGF and TGF-β

Abstract: A free full-text copy of this article can be found at the web page of Upsala J Med Sci: http://www.ujms.se

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
8
0

Year Published

2006
2006
2013
2013

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 21 publications
(8 citation statements)
references
References 37 publications
0
8
0
Order By: Relevance
“…Instead, various approaches have been utilized to antagonize the tumor promotion activity of TGF-β. The involvement of TGF-β in cancer and other diseases makes clinically useful antagonists highly desirable [69]. Inhibiting the production of TGF-β or signaling by TGF-β with anti-TGF-β antibodies, anti-sense RNA, over-expression, or soluble TGF-β receptors may inhibit tumor progression.…”
Section: Tgf-β Antagonists For Inhibition Of Tumor Progressionmentioning
confidence: 99%
“…Instead, various approaches have been utilized to antagonize the tumor promotion activity of TGF-β. The involvement of TGF-β in cancer and other diseases makes clinically useful antagonists highly desirable [69]. Inhibiting the production of TGF-β or signaling by TGF-β with anti-TGF-β antibodies, anti-sense RNA, over-expression, or soluble TGF-β receptors may inhibit tumor progression.…”
Section: Tgf-β Antagonists For Inhibition Of Tumor Progressionmentioning
confidence: 99%
“…Imatinib is a PDGF receptor tyrosine kinase inhibitor that has been shown to ameliorate chronic allograft nephropathy. 245 The insulinlike growth factor (IGF) system is composed of IGF-I and -II, the IGF receptors (types I and II), and IGF binding proteins (IGFBPs), as well as a range of IGFBP proteases, 1,246,247 and are expressed in temporal and tissue-specific manners. The family is regulated by numerous factors, including hormones, growth factors, and physiological parameters, including nutrition, injury, and disease.…”
Section: Other Profibrotic Mediatorsmentioning
confidence: 99%
“…Macrophage recruitment to the site of injury is further sustained by other chemoattractants as well as thrombin, plasmin, platelet factor 4, and platelet-activating factor released from endothelial cells or activated neutrophils. [15][16][17][18][19][20][21][22][23][24][25][26][27] The recruitment of inflammatory and immune-related cells such as macrophages, neutrophils, T cells, and mast cells (which are the sources of many of these molecules) into the wound is also facilitated by adhesion molecules, extracellular matrix such as fibronectin and vitronectin, Figure 1 Schematic representation of regulatory involvement of TGF-b and interactions with several angiogenic cytokines, chemokines, and growth factors that lead to either peritoneal wound healing or adhesion formation. Glu-Leu-Arg or ELR À chemokines, depending on the presence or absence of a sequence of three amino acids (Glu-Leu-Arg) in their N terminus.…”
Section: Molecular Mediatorsmentioning
confidence: 99%